PRESENTATION OF THE INTERIM REPORT JANUARY- JUNE 2011
Invitation
Karo Bio publishes its interim report on July 13 2011 at 8.30 am CET. At 10:00 am CET, acting President Per Bengtsson will present the report in an audiocast. The presentation will be held in Swedish and can be followed by audiocast on the following link:
http://www.financialhearings.nu/110713/karobio/
Please use the following numbers to participate by telephone:
+46 (0)8 5051 3786
+44 (0)20 7136 2052
Enter Confirmation Code: 1944618
For further information please contact:
Per Bengtsson, acting President
Cell phone: +46 734 474 128
About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for unmet medical needs. Karo Bio’s vision is to become a pharmaceutical company with sustainable profitability, commercial products and a competitive project portfolio.
Karo Bio runs a number of development projects within the indication areas cardiovascular and metabolic diseases, neuropsychiatry, inflammatory conditions, autoimmune diseases, cancer and women’s health. An important foundation for the company’s activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Important processes and competencies within the company include structurally based research, drug discovery, preclinical and clinical development, and medical and regulatory expertise.
Karo Bio has the capacity to process select compounds for niche indications through the whole development chain, while compounds addressing large patient groups require development collaborations or out-licensing at some stage in the process. In addition to proprietary projects, Karo Bio has three strategic collaborations with international pharmaceutical companies.
Karo Bio, headquartered in Huddinge, has 70 employees, and is listed on NASDAQ OMX Stockholm since 1998 (Reuters: KARO.ST).
This press release is also available online at www.karobio.com and www.newsroom.cision.com